The work of the Quantitative Medicine Program at the Critical Path Institute (C-Path) focuses on the development and innovation of quantitative solutions for medical product development and clinical needs. Our goal is to leverage knowledge from a network of experts in industry, academia, non-profit and regulatory sciences combined with data acquired from multiple sources to develop quantitative methodologies in pharmacometrics, statistics, systems pharmacology, artificial intelligence and digital data analytics. The solutions developed by QuantMed are often formally reviewed by regulatory agencies as fit-for-purpose in a drug development context. Because QuantMed’s philosophy is one of open science, solutions developed are publicly available as open source platforms. The QuantMed program is highly collaborative, seeking to advance the development of novel treatments for patients with unmet medical needs. The Quantitative medicine program supports multiple public-private partnerships at C-Path focusing on the generation of model informed drug development solutions (MIDD).
The Quantitative Medicine Program’s goals are to
- Lead the generation of advanced data-driven quantitative solutions across C-Path’s public-private partnerships
- Drive innovation in MIDD, AI, and digital health technologies through collaborations with industry, academia, regulators and professions societies
- Provide sound consensus-based knowledge to the intersection of quantitative methodologies and regulatory science.
Our mission is to improve population and individual health by transforming medical product development through methodological innovation.
Our vision is to become a nationally and internationally recognized program of excellence for Model-Informed Drug Development (MIDD).